Posted by Michael Wonder on 16 Jun 2022
Novartis receives GB licence for Scemblix (asciminib), the first STAMP inhibitor for patients with chronic myeloid leukaemia
16 June 2022 - Asciminib is the first treatment in its class to be authorised in Great Britain.
Novartis UK has announced that Scemblix (asciminib) has been granted marketing authorisation in Great Britain by the MHRA to treat adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase, previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.
